ASMB Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
Tagesvolumen	10 133.00
Durchschnittsvolumen	26 439.00
Marktkapitalisierung	70.73M
EPS	$0 ( 2024-03-27 )
Nächstes Ertragsdatum	( $-2.74 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0.275 (2.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Mchutchison John G	Sell	1 206	Common Stock
2024-03-29	Bjorkquist Jeanette M	Buy	850	Common Stock
2024-04-01	Bjorkquist Jeanette M	Sell	114	Common Stock
2024-03-29	Bjorkquist Jeanette M	Buy	1 550	Stock Option (right to buy)
2024-03-29	White Nicole S	Buy	17 500	Stock Option (right to buy)

INSIDER POWER
65.38
Last 96 transactions
Buy: 4 380 980 \| Sell: 646 377

Assembly Biosciences Inc Korrelation

10 Am meisten positiv korreliert
CYAN	0.933
EYEG	0.925
AGFY	0.923
FTFT	0.908
CPIX	0.908
SRTS	0.906
AFIB	0.905
ACER	0.904
DSWL	0.9
ATHA	0.9

10 Am meisten negativ korreliert
DNUT	-0.904
NRDS	-0.897
DSPG	-0.897
EPZM	-0.893
XOG	-0.892
SGEN	-0.889
CNCE	-0.885
TYHT	-0.881
BTBD	-0.875
STAY	-0.874

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Assembly Biosciences Inc Finanzdaten

Annual	2023
Umsatz:	$7.16M
Bruttogewinn:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
Umsatz:	$7.16M
Bruttogewinn:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
Umsatz:	$0
Bruttogewinn:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
Umsatz:	$6.25M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Echtzeitaktualisierungen für Assembly Biosciences Inc [ASMB]

Upcoming Earnings Alert